Related Experiment Video

Updated: Mar 26, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.9K

Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a

Xiao-Zhen Lv1, Zheng Shu1, Yao-Wen Zhang1

  • 1Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.

Translational Pediatrics
|February 3, 2016
PubMed

Insights

Methylphenidate controlled-release (OROS-MPH) may be more effective than immediate-release methylphenidate (IR-MPH) for treating ADHD in children. Atomoxetine (AHC) and IR-MPH showed similar effectiveness, with all treatments demonstrating comparable safety profiles.

Area of Science:

  • Pediatric Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder in children.
  • Pharmacological interventions are a cornerstone of ADHD management.
  • Comparative effectiveness of different ADHD medications in Chinese children requires further investigation.

Purpose of the Study:

  • To compare the efficacy and safety of methylphenidate immediate-release tablets (IR-MPH), methylphenidate controlled-release tablets (OROS-MPH), and atomoxetine (AHC) in Chinese children diagnosed with ADHD.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and clinical controlled trials.
  • Searched major electronic databases including CNKI, VIP, CBMDISC, PubMed, Embase, and MEDLINE.
  • Data extraction and quality assessment performed independently by two reviewers.

Main Results:

  • Eight trials were included, demonstrating the effectiveness of IR-MPH, OROS-MPH, and AHC for ADHD.
  • OROS-MPH showed superiority over IR-MPH in improving peer relationships, clinical global impression-improvement scores, maternal satisfaction, and psychosomatic issues.
  • No significant differences in effectiveness were observed between AHC and IR-MPH. Adverse event incidence rates were comparable across all three treatments and generally mild.

Conclusions:

  • OROS-MPH likely offers superior effectiveness compared to IR-MPH for ADHD treatment in this population.
  • AHC and IR-MPH exhibit similar therapeutic effectiveness.
  • All three medications (IR-MPH, OROS-MPH, AHC) possess equivalent safety profiles and good tolerability in Chinese children with ADHD.
Abstract

Keywords:
Methylphenidateatomoxetineattention deficit hyperactivity disorderchildsystematic review

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

6.6K
Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

11.1K

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
818